As Mentor by eDriving Passes 3.5 Billion Miles Driven, Analysis Confirms Program’s Ability to Reduce Risky Driving Behaviors ACN Newswire

As Mentor by eDriving Passes 3.5 Billion Miles Driven, Analysis Confirms Program’s Ability to Reduce Risky Driving Behaviors

January 26, 2023
CAPE MAY, NJ, Jan 26, 2023 - (ACN Newswire via SEAPRWire.com) - eDriving's digital driver safety program, Mentor(SM), featuring the FICO(R) Safe Driving Score, helps risky drivers become safer behind the wheel in just six months - and further improves behaviors over longer periods of time - according to findings from an analysis of the program. The analysis was performed after the program reached the milestone marking 3.5 billion miles driven in Spring 2022. The eDriving study identified the initial risk level of active[1] business drivers using the Mentor app (i.e., Very High Risk, High Risk, Medium Risk, Low Risk or Very Low Risk[2]), based on their first month's FICO Safe Driving Score - a score derived from smartphone-based driving behavior telematics. It then measured progress[3] over periods of six months, 12 months, and 18 months of using the app.Over a six-month period, those initially categorized as Very High Risk or High Risk experienced up to a 51% increase in their FICO Safe Driving Score, moving them up into the Medium Risk category. Over a longer period of 18 months, those initially categorized as Very High Risk or High Risk experienced an even greater average increase in their FICO Safe Driving Score of up to 70%, moving them up into the Low Risk category.While FICO Safe Driving Score improvement was the most significant for drivers who were initially identified as Very High Risk or High Risk, those identified as Medium Risk also improved, and Low-Risk drivers maintained their good performance levels.The study also showed there was a significant decrease in the negative driving behaviors measured by Acceleration, Braking, Cornering, Phone Distraction, and Speeding events for business drivers using Mentor's patented approach involving driver scoring, eLearning, gamification, and coaching.Speeding Reduction- Over a six-month period, those initially categorized as Very High Risk or High Risk experienced up to a 57% decrease in Speeding events.- Over a period of 18 months, those initially categorized as Very High Risk or High Risk experienced up to an 85% decrease in Speeding events, confirming a sustained improvement in driver behavior when using the Mentor app over a longer period.Distraction Reduction- Over a six-month period, those initially categorized as Very High Risk or High Risk experienced up to a 60% decrease in Distraction events.- Over an 18-month period, those initially categorized as Very High Risk or High Risk experienced up to an 88% decrease in Distraction events, again demonstrating a significant and sustained improvement in driver behavior when using the multi-faceted Mentor program over a longer period.Other significant findings:- Mentor use showed a reduction of in-vehicle calls among Very High-Risk or High-Risk drivers by up to 53% over a six-month period and 85% over 18 months. Phone manipulations (i.e., texting or handling the phone while driving) were reduced among these risky drivers by up to 62% over 6 months and 89% over 18 months.- Over a six-month period, those initially categorized as Very High Risk or High Risk experienced up to a 62% decrease in Hard Acceleration, Hard Braking and Hard Cornering events, with up to an 89% decrease over 18 months."Mentor was designed from the ground up to support our global clients who made the safety of their employees driving for work purposes a strategic imperative," said Ed Dubens, Founder and CEO of eDriving. "Over 20 years of driver risk management combined with the FICO Safe Driving Score, delivers the perfect combination of leading and lagging indicators to help Mentor proactively identify the most at-risk drivers for further support and coaching. 3.5 Billion Mentor miles later, it is incredible to see how quickly we have been able to turn smartphones from villains into catalysts for positive change that can save the lives of not just drivers, but also those they share the road with including pedestrians and cyclists."Launched globally in 2018, Mentor by eDriving is used by organizations around the world to help improve driver behavior among employees driving for work purposes, and has been shown to reduce collisions by up to 67%. The digital program uses smartphone sensors to collect and analyze data on the driving behaviors most predictive of risk. These include Acceleration, Braking, Cornering, Speeding, and Phone Distraction, one of the biggest threats to road safety today.Through eDriving's partnership with industry analytics leader FICO, driver on-road performance is converted into an individual FICO Safe Driving Score, which has been validated to help predict the likelihood of a driver being involved in a collision. Personalized insights are provided privately to drivers after each trip, showing both positive and negative driving events and exactly where they occurred. Additionally, engaging, interactive micro-training modules are delivered directly to the driver in-app to help promptly remediate identified risky behaviors. At the time of the 3.5B mile analysis, over 7.7 million eLearning modules had been viewed by Mentor users. Gamification and rewards are also employed by Mentor to promote driver engagement and friendly competition, while coaching support is included to help sustain behavior improvements over time."The FICO Safe Driving Score continues to provide a consistent and objective measure of driver risk," said Rachel Bell, Vice President of Scores and Analytics at FICO. "We are pleased to see that the FICO Safe Driving Score continues to help organizations keep their drivers safe and limit risks on the road."About SoleraSolera is the global leader in vehicle lifecycle management software-as-a-service, data, and services. Through four lines of business - vehicle claims, vehicle repairs, vehicle solutions and fleet solutions - Solera is home to many leading brands in the vehicle lifecycle ecosystem, including Identifix, Audatex, DealerSocket, Omnitracs, LoJack, Spireon, eDriving/Mentor, Explore, cap hpi, Autodata, and others. Solera empowers its customers to succeed in the digital age by providing them with a "one-stop shop" solution that streamlines operations, offers data-driven analytics, and enhances customer engagement, which Solera believes helps customers drive sales, promote customer retention, and improve profit margins. Solera serves over 300,000 global customers and partners in 100+ countries. For more information, visit www.solera.com.About eDrivingeDriving, a Solera company, helps organizations around the world improve safety, reduce injuries, license violations, carbon emissions, and total cost of fleet ownership through its patented digital driver risk management programs. These include the Mentor by eDriving(SM) smartphone app with FICO(R) Safe Driving Score; the patented, five-stage Crash-Free Culture(R) risk reduction program; and the Virtual Risk Manager(R) platform, all designed to work together within a privacy-first, data-secure environment that supports drivers and their managers every step of the way. eDriving is the digital driver risk management partner of choice for many of the world's largest organizations, supporting over 1,200,000 drivers in 125 countries. Over the past 25 years, eDriving's research-validated programs have been recognized with over 125+ awards around the world. For more information, visit www.edriving.com.Press contact, eDriving:Sheila Leveronepress@edriving.comAbout FICOFICO (NYSE:FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, telecommunications, health care, retail, transportation and supply chain, and many other industries. Using FICO solutions, businesses in more than 120 countries do everything from protecting 2.6 billion payment cards from fraud, to helping people get credit, to ensuring that millions of rental cars are in the right place at the right time. Learn more at https://www.fico.com/.Press contact, FICO:Julie Huangpress@fico.com+1 925-405-7803[1] At least one trip per month[2] FICO(R) Safe Driving Scores were initially categorized as Risky, Poor, Average, Good and Great. These were updated to the new corresponding categories on July 29, 2020.[3] Analysis used data from trips classified as 'Business' only (no 'Passenger' or 'Personal' trips)Mentor Product Sheet https://www.edriving.com//wp-content/themes/edriving/images/pdf/ProductSheets/mentor_ENT_product_sheet.pdfSOURCE: eDriving Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Fosun International Expects One-off Negative Impact to be Cleared and Businesses to Bound Back in 2023

January 21, 2023
HONG KONG, Jan 21, 2023 - (ACN Newswire via SEAPRWire.com) - On 20 January 2023, Fosun International Limited ("Fosun International" or "Fosun", HKEX: 00656) issued a profit warning announcement on the Hong Kong Stock Exchange, mentioning that based on the information available to the Board and the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2022, Fosun International's revenue in 2022 is expected to increase by approximately 10% compared to that of 2021. However, due to the recurrent outbreak of COVID-19 pandemic in 2022 and the turmoil and downturn of the international capital markets, which resulted to an increase in business costs and an increase in floating losses in secondary capital market investment, Fosun International's overall industry operations and industrial investment have been affected to varying degrees, thus the profit attributable to owners of the parent in 2022 is expected to be not more than approximately RMB2 billion.The announcement also pointed out that with the gradual return to normalization of international trade and commerce in 2023, the Company's management expects to see recovery of its businesses. Looking ahead, the Company will further focus on the family-oriented consumer industry and continue to strengthen its global operations to provide quality products and services to families worldwide.Market analyst believes that as the "one-off" negative impact of the external environment clears, Fosun's continuous focus on the family-oriented consumer sector will usher in an important period of opportunity for business rebound in 2023. Since the beginning of the year, Fosun's main businesses centering on household consumption, such as Health, Happiness, and Wealth, have shown signs of strong recovery. It is worth noting that Fosun's forward-looking efforts in the anti-epidemic field have gradually borne fruit.The two flagships of Fosun's Happiness segment, Fosun Tourism Group and Yuyuan, and other businesses have shown strong signs of recovery. According to public information, when the domestic tourism industry suffered a huge setback in 2022, Fosun Tourism Group still stood firm to build global presence and opened seven new Club Med resorts throughout the year. According to market sources, Club Med's global bookings in the first half of 2023 have greatly exceeded the same period in 2019 before the pandemic. During the 2023 New Year holiday period, Atlantis Sanya, FOLIDAY Town Lijiang and other businesses in China all performed better than their respective pre-pandemic levels, and many Club Med resorts in China recorded close to 100% occupancy. During the 2023 New Year holiday period, the 2023 Yuyuan Garden Lantern Festival in the Grand Yuyuan attracted a large number of tourists. It is expected that the Spring Festival will further unleash consumption vitality.Taking the Health segment as another example, Fosun's anti-epidemic "vaccine and drug" products have attracted great attention from the market. On 19 December 2022, COMIRNATY(R), including the monovalent COVID-19 mRNA vaccine (BNT162b2) and the bivalent vaccine which can protect against the Omicron variant, was officially registered as a drug/product (biological product) in Hong Kong SAR. The self-paid vaccination service of COMIRNATY(R) bivalent vaccine was launched in Hong Kong SAR and vaccination is open to people including Mainland Chinese residents starting from 6 January 2023. After the self-paid vaccination service of COMIRNATY(R) monovalent COVID-19 mRNA vaccine has opened for non-local residents in Macau SAR last year, the COMIRNATY(R) bivalent vaccine was approved by Macao SAR as a regular imported vaccine on 20 January 2023, and people in need may receive a booster dose with prescription. As regards Azvudine, the oral medication for COVID-19, it is now included in the medical insurance scheme in 31 provinces, autonomous regions, and direct-administered municipalities across the country. In addition to tertiary hospitals and secondary hospitals, Azvudine has gradually covered grassroots medical institutions in many provinces. The accessibility of Azvudine has been greatly enhanced, helping the vast areas build a barrier against severe cases.As Guo Guangchang, Chairman of Fosun International, mentioned in his 2023 New Year's message, despite the headwinds of anti-globalization in 2022, Fosun is still a firm practitioner of globalization. In 2022, COMIRNATY(R) COVID-19 mRNA vaccine continued to provide an anti-epidemic barrier for Hong Kong SAR, Macao SAR and the Taiwan region; Club Med opened new resorts; Lanvin Group was successfully listed on the New York Stock Exchange. In the face of uncertainties, Fosun remained committed to technology and innovation in order to weather market cycles. HANQUYOU, independently developed by Henlius, was successfully launched in Australia after entering the European Union market; the registration application in the Chinese Mainland for the new indication of Yi Kai Da, China's first CAR-T cell therapy was officially accepted. Fosun attaches great importance to its development. No matter how policies and markets change, Fosun will always devote its best efforts.Fosun's solid fundamentals and recovery potential have been widely recognized by financial institutions and investors. On 16 January 2023, Shanghai Fosun High Technology (Group) Co., Ltd. ("Fosun High Technology"), the domestic operating entity of Fosun International, received a RMB12 billion syndicated loan from eight domestic banks. This is the largest private enterprise loan led by five major state-owned banks in cooperation with policy banks and joint-stock banks since the Central Economic Work Conference explicitly proposed in December 2022 to encourage and support the development of the private economy and private enterprises. Moreover, Fosun High Technology successfully completed bookbuilding for the RMB1 billion super & short-term commercial paper on 13 January 2023.Fosun's financing channels have been further expanded, and the financing costs have been further reduced, consolidating liquidity support for its business recovery. Recently, international rating agency S&P Global Ratings, and investment banks including Morgan Stanley and Daiwa Capital Markets have published research reports, expressing their optimism on Fosun.On 17 January 2023, S&P Global Ratings pointed out in a report that Fosun International's newly signed syndicate loan will largely cover onshore bonds due within a year. Fosun International's total debt at the holding company level could drop by 15%-25% in 2023 as the company continues to dispose assets and pay down matured bonds, thereby further improving its liquidity. S&P Global Ratings also noted that Fosun High Technology's successful issuance of the super & short-term commercial paper was Fosun's first issuance in the onshore market after a nine-month hiatus, marking a first baby step and indicating a recovery of the public bond market access. According to incomplete statistics, Fosun's return of capital from its asset reduction in 2022 has reached tens of billions of yuan, further consolidating its capital.On the same day, Morgan Stanley also issued a report commenting that Fosun's syndicated loan can further improve its liquidity, significantly helping lift market confidence in Fosun's stability. The firm believes that after several months of active deleveraging efforts, Fosun's liquidity risk has been greatly reduced. Looking ahead, the reopening of China will help boost fundamentals, especially in businesses such as tourism, retail, and investment.Previously, Nomura Orient International Securities, China Industrial Securities, and China International Capital Corporation (CICC) have published research reports, expressing their optimism about Fosun's strategy of streamlining the organization and focusing on its core businesses. Nomura Orient International Securities pointed out that Fosun has firmly promoted and focused on its core businesses in the family-oriented sector at the operational level. With the continuous optimization of China's epidemic prevention and control measures, the firm expects Fosun to achieve better performance. CICC believes that in the medium and long term, the valuation method of Fosun International is expected to gradually shift from using the NAV of the group to using the PE of the large consumer company. As a result, Fosun is expected to usher in a rise in the central level of long-term valuation.Based on Fosun's solid financial performance and strong potential for rebound, Morgan Stanley and Daiwa Capital Markets reiterated their "Overweight"/"Buy" rating on Fosun International. Nomura Orient International Securities, China Industrial Securities, and CICC have assigned Fosun International an "Overweight"/"Outperform" rating. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Fosun Receives RMB12 Billion Syndicated Loan to Consolidate Capital for Business Development

January 17, 2023
HONG KONG, Jan 17, 2023 - (ACN Newswire via SEAPRWire.com) - On 16 January 2023, Fosun High Technology, the domestic operating entity of Fosun International Limited ("Fosun International", HKEX: 00656), and eight domestic banks held a syndicated loan signing ceremony at the Bund Finance Center, Shanghai. According to the agreement, Industrial and Commercial Bank of China, Agricultural Bank of China, Bank of China, China Construction Bank, and Bank of Communications as joint lead banks, and China Minsheng Bank, the Export-Import Bank of China, and Shanghai Pudong Development Bank, and as participating banks will jointly form a syndicate to provide Fosun High Technology a loan totaling RMB12 billion.It is reported that this is the largest private enterprise loan led by five major state-owned banks in cooperation with policy banks and joint-stock banks since the Central Economic Work Conference explicitly proposed in mid-December last year to encourage and support the development of the private economy and private enterprises.The market is generally in the view that the syndicated loan is not only of great significance to Fosun, but it also plays a positive role in improving public expectations and boosting confidence for development for private enterprises in Shanghai and even the entire country.According to the Company's official release, Guo Guangchang, Chairman of Fosun International said that this signing has further deepened the cooperation between Fosun and banks, broadened financing channels, and consolidated liquidity support for business development.Before the RMB12 billion syndicated loan was officially completed, on 13 January, Fosun High Technology successfully completed bookbuilding for the RMB1 billion super & short-term commercial paper "23 Fosun High Technology SCP001" with a term of 180 days and a coupon rate of 6.99% per annum. The super & short-term commercial paper is Fosun High Technology's first issuance since its return to the public market at the end of April 2022.Market analyst pointed out that the successful issuance of the super & short-term commercial paper and the smooth completion of more than RMB10 billion syndicates loan reflect financial institutions and investors' confidence in the stabilization of Fosun's capital and their endorsement of Fosun's strategy of streamlining the organization and focusing on its core businesses.Over the past six months or so, Fosun's series of divestment actions in the capital market have gained widespread attention. During the period, companies under Fosun significantly reduced their shareholdings in Nanjing Iron and Steel United, Jianlong, Zhaojin Mining, Tsingtao Brewery, Jinhui Liquor, Zhongshan Public Utilities, Sanyuan, and COFCO Engineering & Technology. According to incomplete statistics, Fosun's accumulative return of capital has reached tens of billions of yuan. In addition to this syndicated loan and the super & short-term commercial paper, Fosun's capital has been further consolidated.In recent years, Fosun proposed to position itself as a global innovation-driven consumer group. In the past six months or so, Fosun has significantly accelerated its pace of focusing on its core businesses in the family-oriented consumer sector. Based on recent positive news, it can be seen that this strategic adjustment has already achieved results, and Fosun's Health, Happiness, Wealth and other family-oriented consumer sectors have shown a strong recovery momentum.Taking Fosun Tourism Group in the Happiness segment as an example, on the New Year's Day this year, Atlantis Sanya, FOLIDAY Town Lijiang and other businesses have all performed better than the same period in 2022, and many Club Med resorts in China recorded close to 100% occupancy. In the global market, Club Med's bookings in the first half of 2023 have greatly exceeded the same period in 2019 before the COVID-19 epidemic.Regarding Fosun Pharma in the Health segment, its anti-epidemic vaccine and drug continue to attract great attention. COMIRNATY, including the monovalent COVID-19 mRNA vaccine (BNT162b2) and the bivalent vaccine which can protect against the Omicron variant, was officially registered as a drug/product (biological product) in Hong Kong SAR on 20 December 2022. Fosun Pharma has also opened up vaccinations to people including Mainland Chinese residents. As regards Azvudine, the oral medication for COVID-19, it is now included in the medical insurance scheme in 31 provinces, municipalities, and autonomous regions across the country, and is available in grassroots medical institutions in many provinces. The accessibility of Azvudine has been greatly enhanced.Based on its solid financial performance and strong potential for rebound, domestic and overseas securities firms have recently issued research reports, assigning Fosun International an "overweight" rating. On 12 January, Nomura Orient International Securities published a research report and mentioned that Fosun International currently has sufficient cash flow, the short-term liquidity problem has been resolved, the future leverage ratio is expected to be reduced, and the capital structure will continue to be optimized; at the operational level, Fosun will firmly focus on its core businesses in the family-oriented consumer sector. With the continuous optimization of China's epidemic prevention policy, the firm expects Fosun to achieve better performance.Previously, China International Capital Corporation (CICC) and China Industrial Securities have published research reports successively and expressed optimism about Fosun's strategy of streamlining the organization and focusing on its core businesses."In the medium and long term, we believe that the valuation method of Fosun International is expected to gradually shift from using the NAV of the group to using the PE of the large consumer company. As a result, Fosun is expected to usher in a rise in the central level of long-term valuation," CICC mentioned in the research report. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
兆科眼科的合作伙伴Vyluma发表用于治疗儿童近视加深的NVK002之第III期CHAMP临床试验的正面研究结果 ACN Newswire

兆科眼科的合作伙伴Vyluma发表用于治疗儿童近视加深的NVK002之第III期CHAMP临床试验的正面研究结果

October 28, 2022
HONG KONG, Oct 28, 2022 - (亚太商讯 via SEAPRWire.com) - 致力于眼科疗法的研发、生产及商业化，以满足巨大医疗需求缺口的领先眼科制药企业兆科眼科有限公司（「兆科眼科」或「本公司」; 香港联交所股份代号： 6622） 欣然宣布，公司的合作伙伴Vyluma Inc. （「Vyluma」），一家拥有多种屈光不正治疗产品的生物制药公司，发表了其针对儿童加视加深的第III期临床研究「CHAMP」的首要结果。 经过三年的治疗和跟进，这项多中心、国际性的试验的研究分析表明，NVK002作为儿童近视加深的潜在治疗方案，具有强健的安全性和有效性。 CHAMP的研究结果已于10月27日在加州圣地亚哥举行的美国视光学会年会上进行了口头汇报。 Vyluma创始人、董事长兼首席执行官Navneet Puri博士表示：「CHAMP是迄今为止规模最大、时间最长、及具安慰剂对照的前瞻性儿童近视研究。我们对第一阶段的试验结果感到备受鼓舞。近视是一种日益严重的全球流行眼疾，威胁着数以百万计的儿童，对他们将来的视力产生严重影响，惟近视目前还没有获监管机构批准的药物治疗方案。我们正在对数据进行分析，从而评估全面结果，但目前得到的首要结果，清楚刻划了近视控制的一个重要里程碑，标志着一个潜在的、更有希望的新时代即将到来。」由 Vyluma研发的NVK002，是一款具有专利配方、试验性、低剂量兼不含防腐剂、每晚使用的阿托品滴眼液。NVK002以一种新的低剂量兼不含防腐剂的配方，运用人们熟知的特性良好的治疗剂——阿托品，帮助解决以药物控制近视的迫切需求。CHAMP是一项在美国和欧洲进行的三臂、随机、双盲及安慰剂对照的III期临床研究，试验对象数目达近600名3至17岁的儿童和青少年。该研究包括两个阶段：（1）完成三年的治疗期，以评估NVK002的安全性和有效性；（2）及之后入组患者将重新随机进行为期一年的单盲治疗，以归纳停止疗程的特征。与安慰剂组相较，使用0.01%阿托品剂量组患者在所有关键结果测量上，包括缓解者分析（responder analysis）、平均等效球面度数（SER）、在第36个月时与基线相较的平均眼轴长度等，都显示出具统计与临床意义上的差异。0.02%阿托品剂量亦在许多时间点上展现疗效，包括在第36个月时达成统计上显著的平均眼轴长度变化。缓解者分析结果在36个月时无统计显著性。两种浓度的NVK002都表现出与安慰剂相似的强健的安全性和耐受性，没有发生眼部严重不良反应（SAEs）。非眼部严重不良反应（SAEs）的发生率和因非眼部严重不良反应（SAEs）而停药的情况在各治疗组中相似。最常见的眼部不良反应有充血、畏光、过敏性结膜炎、眼部瘙痒症和眼部刺激症状。视光学博士、美国眼科视光医学会会员、Optometry and Physiological Optics学术期刊首席研究员、Glenn A. Fry教授兼俄亥俄州立大学验光学院院长Karla Zadnik博士表示：「近视是一种影响着现今全球30%人口视力的严重疾病，预计影响人数将于2050年增至50亿人，因此近视问题需尽早解决。 CHAMP研究证明了Vyluma的低剂量阿托品的新配方，可以在治疗儿童近视方面产生具临床意义的作用。这项新证据增加了我们对安全和有效方法的科学理解，用以协助我们解决这个日益加剧的全球问题。」Vyluma 已与 Laboratoires Théa和兆科眼科合作进行NVK002的商业化。 Laboratoires Théa 是欧洲领先的独立眼科医药集团，将负责 NVK002在欧洲的商业化，以及在加拿大、墨西哥和特定南美国家的注册和商业化。兆科眼科是一家领先的眼科制药公司，将负责 NVK002在大中华区、韩国和特定东南亚国家（文莱、缅甸、柬埔寨、东帝汶、印度尼西亚、老挝、马来西亚、菲律宾、新加坡、泰国和越南）的临床开发和商业化。兆科眼科董事会主席、执行董事兼行政总裁李小羿表示：「在中国，数以亿计的儿童和青少年患有近视。我们对美国和欧洲令人鼓舞的数据感到兴奋。这为我们兆科眼科向中国监管机构提交 NVK002的新药申请提供了有力支撑。我们的目标是尽快将NVK002推向市场，而Vyluma今次的研究结果使我们在改变中国视觉健康的使命上，再向前迈进了一步。」Vyluma 计划最早于 2023 年第一季度向美国食品药品监督管理局（FDA）提交 NVK002 的新药申请。若获得 FDA 批准，NVK002 将成为市场首款经临床证明的用于治疗儿童近视加深的药物。有关 Vyluma 和 NVK002 的更多信息，请浏览 www.vyluma.com。关于近视近视是一种严重且不可逆转的眼疾，会因眼球拉长而导致视力丧失。 它被认为是一种日益严重的全球流行病，预计到 2050 年将影响大约一半的世界人口1。 受到新冠病毒疫情的影响3，在电子屏幕上近距离工作的机会增加和户外时间减少，近视的情况正在加速蔓延。 若不及早治疗，童年时期的近视将增加以后视力丧失和眼部并发症的风险，例如白内障、青光眼和视网膜疾病4。因为5 至 15 岁之间眼睛发育迅速，故近视在此期间发展得最快5。仅透过非渐进式隐形眼镜及普通眼镜矫正视力，并不会减缓近视的发展，这将使儿童在将来的生活中面临严重的风险6,7,2。关于Vyluma Inc.Vyluma Inc. 是一家专注于治疗屈光不正眼疾的生物医药研发公司。Vyluma Inc.的强大药物管线遍布各个临床阶段，藉此满足屈光不正或眼痛患者的巨大治疗需求缺口。Vyluma Inc.为 Nevakar Inc. 的全资子公司，Nevakar Inc.是一家控股公司，其子公司专注眼科和注射市场的产品开发。欲查询更多信息，请浏览： www.vyluma.com 关于Nevakar Inc.Nevakar Inc.为一家全面整合的后期生物医药私人公司，拥有丰富的眼科及可注射产品组合。 Nevakar Inc.于2015年创立，总部设于新泽西布里奇沃特（Bridgewater New Jersey），专门开发及商业化生产能填补医疗需要真空的创新产品，进而提升病人护理及生活质素。 Nevakar Inc.利用505(b)(2) 监管途径，以及其在开发新型和专有无菌药物产品方面的公认专业知识来识别、开发、并取得其产品的相关监管批准。如欲获得更多信息，请浏览www.nevakar.com 关于兆科眼科有限公司兆科眼科（香港联交所股份代号：6622）成立于2017年，是一家领先的眼科制药企业，致力于眼科疗法的研发、生产及商业化，以满足巨全球大医疗需求缺口。兆科眼科于2021年4月29日在香港联交所主板上市。兆科眼科已建立由创新药及仿制药组成的候选药物，涵盖影响眼前节及眼后节的6种主要眼科适应症。众多药物现时由位于广州南沙最先进并已全面运作的生产设施所制造。公司正专注向产品商业化目标推进，务求尽快实现以科研改善中国大众的视力健康。凭借雄心勃勃的增长战略，包括与国内外制药公司携手合作，兆科眼科的目标是成为世界眼科的领导者。欲查询更多信息，请浏览：www.zkoph.com 媒体联络：安达信顾问 Artemis Associates 傅安缇 Diana Footitt，行政总裁M: +852 9183 0667E:diana.footitt@artemisassociates.com徐宝文，总监M: +852 9783 0643E: bowen.chui@artemisassociates.com裴浩慈，总监M: +86 15000 465 016E: iris.pei@artemisassociates.com参考数据：1. Holden, B. A., Fricke, T. R., Wilson, D. A., Jong, M., Naidoo, K. S., Sankaridurg, P., Wong, T. Y., Naduvilath, T. J., & Resnikoff, S. (2016). Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology, 123(5), 1036–1042. https://doi.org/10.1016/j.ophtha.2016.01.006.2. Sankaridurg, P., Tahhan, N., Kandel, H., Naduvilath, T., Zou, H., Frick, K. D., Marmamula, S., Friedman, D. S., Lamoureux, E., Keeffe, J., Walline, J. J., Fricke, T. R., Kovai, V., & Resnikoff, S. (2021). IMI Impact of Myopia. Investigative Opthalmology & Visual Science, 62(5), 2. https://doi.org/10.1167/iovs.62.5.2.3. Rusnak, S., Salcman, V., Hecova, L., & Kasl, Z. (2018). Myopia Progression Risk: Seasonal and Lifestyle Variations in Axial Length Growth in Czech Children. Journal of Ophthalmology, 2018, 1–5. https://doi.org/10.1155/2018/5076454.4. Ritchey, O. E. D., PhD. (2020, September 18). Myopia Increases the Risk of Serious, Sight-Threatening Eye Disease. Review of Myopia Management. https://reviewofmm.com/myopia-increase-the-risk-of-serious-sight-threatening-eye-disease/.5. Verkicharla, P. K., Kammari, P., & Das, A. V. (2020). Myopia progression varies with age and severity of myopia. PLOS ONE, 15(11), e0241759. https://doi.org/10.1371/journal.pone.0241759.6. Deere, K., Williams, C., Leary, S., Mattocks, C., Ness, A., Blair, S. N., & Riddoch, C. (2009). Myopia and later physical activity in adolescence: a prospective study. British Journal of Sports Medicine, 43(7), 542–544. https://doi.org/10.1136/bjsm.2008.049288.7. Wolffsohn, J. S., Jong, M., Smith, E. L., Resnikoff, S. R., Jonas, J. B., Logan, N. S., Morgan, I., Sankaridurg, P., & Ohno-Matsui, K. (2021). IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Investigative Opthalmology & Visual Science, 62(5), 1. https://doi.org/10.1167/iovs.62.5.1. Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More